Lysine methyltransferase SMYD2 enhances androgen receptor signaling to modulate CRPC cell resistance to enzalutamide. Li J, Hong Z, Zhang J, Zheng S, et al. Oncogene 2024;43:744-757.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Li J, Hong Z, Zhang J, Zheng S, et al. Lysine methyltransferase SMYD2 enhances androgen receptor signaling to modulate CRPC cell resistance to enzalutamide. Oncogene 2024;43:744-757.
PMID: 38243079